Cytochrome P450 3A4 Antibody | Affinity Biosciences

Cites

1/3

Product:	Cytochrome P450 3A4 Antibody
Catalog:	DF7001
Description:	Rabbit polyclonal antibody to Cytochrome P450 3A4
Application:	WB IHC IF/ICC
Cited expt.:	WB
Reactivity:	Human, Mouse, Rat
Prediction:	Dog
Mol.Wt.:	57kD(Observed); 57kD(Calculated).
Uniprot:	P08684
RRID:	AB_2838957

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Dog(88%)

Clonality:

Polyclonal

Specificity:

Cytochrome P450 3A4 Antibody detects endogenous levels of total Cytochrome P450 3A4.

RRID:

AB_2838957
Cite Format: Affinity Biosciences Cat# DF7001, RRID:AB_2838957.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

1,8-cineole 2-exo-monooxygenase; Albendazole monooxygenase; Albendazole sulfoxidase; CP33; CP34; CP3A4_HUMAN; CYP3; CYP3A; CYP3A3; CYP3A4; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 3A4; Cytochrome P450 family 3 subfamily A polypeptide 4; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450 subfamily IIIA polypeptide 4; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4; Cytochrome P450-PCN1; Glucocorticoid inducible P450; HLP; MGC126680; NF 25; NF25; Nifedipine oxidase; P450 III steroid inducible; P450 PCN1; P450, family III; P450C3; P450PCN1; Quinine 3 monooxygenase; Quinine 3-monooxygenase; Taurochenodeoxycholate 6 alpha hydroxylase; Taurochenodeoxycholate 6-alpha-hydroxylase;

Immunogens

Immunogen:

A synthesized peptide derived from human Cytochrome P450 3A4, corresponding to a region within the internal amino acids.

Uniprot:

P08684(CP3A4_HUMAN) >>Visit HPA database.

Gene(ID):

CYP3A4(1576)

Expression:

P08684 CP3A4_HUMAN:

Expressed in prostate and liver. According to some authors, it is not expressed in brain (PubMed:19094056). According to others, weak levels of expression are measured in some brain locations (PubMed:19359404 and PubMed:18545703). Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).

Description:

Cytochrome P450 3A(CYP3A) belongs to the cytochrome P450 family and the enzymes constitute an important detoxification system that contributes to primary metabolism of more than half of all prescribed medications.CYP3A expression determines impairment of drug absorption and efficient systemic clearance in a tissue-specific manner(PMID:17975676).This antibody is specific to CYP3A4.

Sequence:

P08684 CP3A4_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Dog

Bovine

Xenopus

Chicken

Pig

Horse

Sheep

Zebrafish

Rabbit

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

P08684_CP3A4_HUMAN

Function:

A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds. Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position. Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone. Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones. Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis. Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond. Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance. Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole. Hydroxylates antimalarial drug quinine. Acts as a 1,4-cineole 2-exo-monooxygenase.

PTMs:

Polyubiquitinated in the presence of AMFR and UBE2G1 and also STUB1/CHIP and UBE2D1 (in vitro).

Subcellular Location:

Endoplasmic reticulum membrane>Single-pass membrane protein. Microsome membrane>Single-pass membrane protein.

Tissue Specificity:

Expressed in prostate and liver. According to some authors, it is not expressed in brain. According to others, weak levels of expression are measured in some brain locationsand. Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).

Family&Domains:

Belongs to the cytochrome P450 family.

Research Fields

· Human Diseases > Cancers: Overview > Chemical carcinogenesis.

· Metabolism > Lipid metabolism > Steroid hormone biosynthesis.

· Metabolism > Lipid metabolism > Linoleic acid metabolism.

· Metabolism > Metabolism of cofactors and vitamins > Retinol metabolism.

· Metabolism > Xenobiotics biodegradation and metabolism > Metabolism of xenobiotics by cytochrome P450.

· Metabolism > Xenobiotics biodegradation and metabolism > Drug metabolism - cytochrome P450.

· Metabolism > Xenobiotics biodegradation and metabolism > Drug metabolism - other enzymes.

· Metabolism > Global and overview maps > Metabolic pathways.

References

1). Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-κB-mediated signaling pathway in vitro and in vivo. Laboratory Investigation, 2021 (PubMed: 34031539) [IF=5.1]

Application: WB Species: Human Sample: liver tissues

Fig. 2 AOPPs downregulated the protein expression and activities of CYP1A2 and CYP3A4 in vivo. Total protein was extracted from the intestine, kidney, and liver in the sham (A) and 5/6 nx groups (B), and the protein expression of CYP1A2 and CYP3A4 in a whole-cell lysate was evaluated by western blotting. Proteins expression levels were quantified by ImageJ software (C, D). Each experiment was performed with a different isolate. Michaelis–Menten plots of acetaminophen (E) and 6β-hydroxytestosterone (F) were constructed after incubation of liver microsomes (extracted from the liver tissues in the sham and 5/6 nx groups) with NADPH and various concentrations of phenacetin or testosterone, respectively, which were used to evaluate the activities of CYP1A2 and CYP3A4, respectively. Each data point represents the mean of three replicates and the error bars represent standard error of the mean (n = 3). Data are presented as mean ± SD; *p < 0.05 compared with the PBS group. Data were normalized to GAPDH.

Application: WB Species: rat Sample: intestine, kidney, and live

Fig. 2 |AOPPs downregulated the protein expression and activities of CYP1A2 and CYP3A4 in vivo. Total protein was extracted from the intestine, kidney, and liver in the sham (A) and 5/6 nx groups (B),and the protein expression of CYP1A2 and CYP3A4 in a whole-cell lysate was evaluated by western blotting. Proteins expression levels were quantified by ImageJ software (C, D).

Application: WB Species: rat Sample: HepG2 or L-02 cells

Fig. 6| AOPPs downregulated CYP1A2 and CYP3A4 expression via the NF-κBpathway. NF-κB-dependent firefly luciferase reporter gene was transfected into HepG2 or L-02 cells, and the reporter gene expression (A). HepG2 or L-02 cells were treated with AOPPs (200 µg/ml) for 48 h and cocultured with BAY-117082 (B) and PDTC (C) to restore the downregulated expression levels of CYP1A2 and CYP3A4.

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

Cytochrome P450 3A4 Antibody - #DF7001